Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals
Autor: | Mark Konijnenberg, Ho Sze Chan, Rory M. S. de Zanger, Erik de Blois, Wouter A.P. Breeman |
---|---|
Přispěvatelé: | Radiology & Nuclear Medicine, Internal Medicine |
Rok vydání: | 2019 |
Předmět: |
lcsh:Medical physics. Medical radiology. Nuclear medicine
Standardization Computer science lcsh:R895-920 Arbitrary unit 030218 nuclear medicine & medical imaging Analytical Chemistry 03 medical and health sciences 0302 clinical medicine Activity detection Pharmacology (medical) Radiology Nuclear Medicine and imaging Pharmacology lcsh:RM1-950 Methodology Reliability engineering RCP lcsh:Therapeutics. Pharmacology 030220 oncology & carcinogenesis Multicenter trial Radiopharmaceuticals HPLC Validated conditions Smoothing Institutional quality |
Zdroj: | EJNMMI Radiopharmacy and Chemistry, 4(1). Springer Science+Business Media EJNMMI Radiopharmacy and Chemistry, Vol 4, Iss 1, Pp 1-13 (2019) EJNMMI Radiopharmacy and Chemistry |
ISSN: | 2365-421X |
Popis: | Background Clinically applied radiopharmaceuticals have to meet quality release criteria like a high radiochemical yield and radiochemical purity. Many radiopharmaceuticals do not have marketing authorization and have no dedicated monograph within the European pharmacopeia, therefore general monographs on quality control have to be applied for clinical applications. These criteria require standardization and validation in labeling and preparation, including QC measurements according to well-defined standard operation procedures. QC measurements however, are often based on detection techniques specific for a certain LC-system. Multi-institutional research and development of new radiopharmaceuticals lead to an increase in multicenter trials. Although all institutes’ radiopharmacies are using the same standardized labeling and operation procedures, they often use different LC and radiodetection systems. Here we present a comparison of QC assessments for 3 radiopharmaceuticals with focus on the interpretation of chromatograms, data-output and potential differences in local practical performances of QC on (U)HPLC. Methods QC assessments for [111In]In-CCK, [68Ga]Ga-Bombesin and [177Lu]Lu-PSMA analogs were compared. Two of the radiopharmaceutical QC assessments were also applied in other institutes using their own HPLC-systems and concordant software. Data from the HPLC-injections and measurements is processed and summarized in chromatograms, based on a variety of smoothing algorithms for which different software programs are applied. Described radiopeptides were labeled and analyzed according their standardized labeling and operation procedures. Results Integration of main peaks on chromatograms resulted in a range of RCP, depending on the smoothing algorithm used. [111In]In-CCK(A), 68Ga-Bombesin(B) and [177Lu]Lu-PSMA(C) analogs had a RCP range of 88%–96%(A), 89–95%(B) and 92–99%(C) respectively. Important factors affecting final RCP value were site specific background radiation-levels, intrinsic system properties such as noise and sensitivity, personal interpretation e.g. peak-tailing and smoothing algorithms. Conclusion Measurement of RCP shows a strong method- and system-dependency, even when parameters are validated, standardized and SOP are followed. Release criteria are frequently based on RCP data from one central location. The lack of inter inter institutional validation and standardization in RCP determination makes the results therefore rather arbitrary. For multicenter trials, we recommend to compare locally determined RCP under validated and standardized conditions of in-line activity detection between institutes for each radiopharmaceutical. |
Databáze: | OpenAIRE |
Externí odkaz: |